In addition, unlike the other HSP90 inhibitors, TAS-116 is an oral drug that is currently in phase 3 clinical trial of gastrointestinal stromal tumors (88, 89). The gene discussed is HSP90AA1; the disease is gastrointestinal stromal tumor.